Human Beta-Defensin 3 Is Up-Regulated in Cutaneous Leprosy Type 1 Reactions

PLoS Neglected Tropical Diseases

Volumn 6, Issue 11, 2012, Pages

  Cogen, Anna L ^a   Walker, Stephen L ^a   Roberts, Chrissy H ^a   Hagge, Deanna A ^b   Neupane, Kapil D ^b   Khadge, Saraswoti ^b   Lockwood, Diana N J ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b Anandaban Leprosy Hospital   (Nepal)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEFENSIN 2; BETA DEFENSIN 3; METHYLPREDNISOLONE; PREDNISOLONE; SODIUM CHLORIDE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLOURESCENCE TEST; KERATINOCYTE; LEPROSY; MACROPHAGE; MYCOBACTERIUM LEPRAE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN BIOPSY; UPREGULATION;

ADRENAL CORTEX HORMONES; BETA-DEFENSINS; BIOPSY; CELLS, CULTURED; GENE EXPRESSION PROFILING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATINOCYTES; LEPROSY, LEPROMATOUS; MACROPHAGES; MYCOBACTERIUM LEPRAE; REAL-TIME POLYMERASE CHAIN REACTION; UP-REGULATION;

EID: 84870732395     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001869     Document Type: Article

References (36)

1. WHO (2009) WHO Status Report.
2. Yamamura M, Uyemura K, Deans RJ, Weinberg K, Rea TH, et al. (1991) Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 254: 277-279.
3. Schenk M, Belisle JT, Modlin RL, (2009) TLR2 looks at lipoproteins. Immunity 31: 847-849.
4. Krutzik SR, Ochoa MT, Sieling PA, Uematsu S, Ng YW, et al. (2003) Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nat Med 9: 525-532.
5. Liu PT, Schenk M, Walker VP, Dempsey PW, Kanchanapoomi M, et al. (2009) Convergence of IL-1beta and VDR activation pathways in human TLR2/1-induced antimicrobial responses. PLoS One 4: e5810.
6. Zanger P, Holzer J, Schleucher R, Scherbaum H, Schittek B, et al. (2010) Severity of Staphylococcus aureus infection of the skin is associated with inducibility of human beta-defensin 3 but not human beta-defensin 2. Infect Immun 78: 3112-3117.
7. Seidel A, Ye Y, de Armas LR, Soto M, Yarosh W, et al. (2010) Cyclic and acyclic defensins inhibit human immunodeficiency virus type-1 replication by different mechanisms. PLoS One 5: e9737.
8. Wilmes M, Cammue BP, Sahl HG, Thevissen K, (2011) Antibiotic activities of host defense peptides: more to it than lipid bilayer perturbation. Nat Prod Rep 28: 1350-8.
9. Vylkova S, Li XS, Berner JC, Edgerton M, (2006) Distinct antifungal mechanisms: beta-defensins require Candida albicans Ssa1 protein, while Trk1p mediates activity of cysteine-free cationic peptides. Antimicrob Agents Chemother 50: 324-331.
10. Boniotto M, Jordan WJ, Eskdale J, Tossi A, Antcheva N, et al. (2006) Human beta-defensin 2 induces a vigorous cytokine response in peripheral blood mononuclear cells. Antimicrob Agents Chemother 50: 1433-1441.
11. Sibley LD, Franzblau SG, Krahenbuhl JL, (1987) Intracellular fate of Mycobacterium leprae in normal and activated mouse macrophages. Infect Immun 55: 680-685.
12. Okada S, Komura J, Nishiura M, (1978) Mycobacterium leprae found in epidermal cells by electron microscopy. Int J Lepr Other Mycobact Dis 46: 30-34.
13. Sato N, Fujimura T, Masuzawa M, Yogi Y, Matsuoka M, et al. (2007) Recombinant Mycobacterium leprae protein associated with entry into mammalian cells of respiratory and skin components. J Dermatol Sci 46: 101-110.
14. Mutis T, De Bueger M, Bakker A, Ottenhoff TH, (1993) HLA class II+ human keratinocytes present Mycobacterium leprae antigens to CD4+ Th1-like cells. Scand J Immunol 37: 43-51.
15. Nizet V, Ohtake T, Lauth X, Trowbridge J, Rudisill J, et al. (2001) Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 414: 454-457.
16. Prado-Montes de Oca E, Velarde-Felix JS, Rios-Tostado JJ, Picos-Cardenas VJ, Figuera LE, (2009) SNP 668C (-44) alters a NF-kappaB1 putative binding site in non-coding strand of human beta-defensin 1 (DEFB1) and is associated with lepromatous leprosy. Infect Genet Evol 9: 617-625.
17. Bochud PY, Hawn TR, Aderem A, (2003) Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling. J Immunol 170: 3451-3454.
18. Kang TJ, Chae GT, (2001) Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients. FEMS Immunol Med Microbiol 31: 53-58.
19. Bochud PY, Hawn TR, Siddiqui MR, Saunderson P, Britton S, et al. (2008) Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. J Infect Dis 197: 253-261.
20. Kang TJ, Lee SB, Chae GT, (2002) A polymorphism in the toll-like receptor 2 is associated with IL-12 production from monocyte in lepromatous leprosy. Cytokine 20: 56-62.
21. Kang TJ, Yeum CE, Kim BC, You EY, Chae GT, (2004) Differential production of interleukin-10 and interleukin-12 in mononuclear cells from leprosy patients with a Toll-like receptor 2 mutation. Immunology 112: 674-680.
22. Bochud PY, Sinsimer D, Aderem A, Siddiqui MR, Saunderson P, et al. (2009) Polymorphisms in Toll-like receptor 4 (TLR4) are associated with protection against leprosy. Eur J Clin Microbiol Infect Dis 28: 1055-1065.
23. Bafica A, Scanga CA, Feng CG, Leifer C, Cheever A, et al. (2005) TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J Exp Med 202: 1715-1724.
24. Zhang FR, Huang W, Chen SM, Sun LD, Liu H, et al. (2009) Genomewide association study of leprosy. N Engl J Med 361: 2609-2618.
25. Montoya D, Cruz D, Teles RM, Lee DJ, Ochoa MT, et al. (2009) Divergence of macrophage phagocytic and antimicrobial programs in leprosy. Cell Host Microbe 6: 343-353.
26. Walker SL, Nicholls PG, Dhakal S, Hawksworth RA, Macdonald M, et al. (2011) A Phase Two Randomised Controlled Double Blind Trial of High Dose Intravenous Methylprednisolone and Oral Prednisolone versus Intravenous Normal Saline and Oral Prednisolone in Individuals with Leprosy Type 1 Reactions and/or Nerve Function Impairment. PLoS Negl Trop Dis 5: e1041.
27. Little D, Khanolkar-Young S, Coulthart A, Suneetha S, Lockwood DN, (2001) Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin-12, and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during prednisolone treatment. Infect Immun 69: 3413-3417.
28. Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, et al. (2006) The continuing challenges of leprosy. Clin Microbiol Rev 19: 338-381.
29. Shetty VP, Khambati FA, Ghate SD, Capadia GD, Pai VV, et al. (2010) The effect of corticosteroids usage on bacterial killing, clearance and nerve damage in leprosy; part 3-Study of two comparable groups of 100 multibacillary (MB) patients each, treated with MDT + steroids vs. MDT alone, assessed at 6 months post-release from 12 months MDT. Lepr Rev 81: 41-58.
30. Yamamura M, Wang XH, Ohmen JD, Uyemura K, Rea TH, et al. (1992) Cytokine patterns of immunologically mediated tissue damage. J Immunol 149: 1470-1475.
31. Joly S, Organ CC, Johnson GK, McCray PB Jr, Guthmiller JM, (2005) Correlation between beta-defensin expression and induction profiles in gingival keratinocytes. Mol Immunol 42: 1073-1084.
32. Grice EA, Segre JA, (2011) The skin microbiome. Nat Rev Microbiol 9: 244-253.
33. Cogen AL, Yamasaki K, Sanchez KM, Dorschner RA, Lai Y, et al. (2010) Selective antimicrobial action is provided by phenol-soluble modulins derived from Staphylococcus epidermidis, a normal resident of the skin. J Invest Dermatol 130: 192-200.
34. Lai Y, Di Nardo A, Nakatsuji T, Leichtle A, Yang Y, et al. (2009) Commensal bacteria regulate Toll-like receptor 3-dependent inflammation after skin injury. Nat Med 15: 1377-1382.
35. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M, (1995) Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270: 286-290.
36. Banerjee A, Gerondakis S, (2007) Coordinating TLR-activated signaling pathways in cells of the immune system. Immunol Cell Biol 85: 420-424.